Apuli Maricel sold $146K of BBIO

Apuli Maricel (Chief Accounting Officer) sold 2,000 shares of BridgeBio Pharma, Inc. (BBIO) at $72.85 ($0.15M total) on 2026-10-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Apuli Maricel
Published Nov 3, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BBIO
Bearish
medium confidence
Mentioned
$BBIO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIOBearishLow
01

Why it matters

The disclosed sale reduces insider ownership modestly, which may be interpreted as a slight bearish signal by the market.

02

Market read

Small insider sale with limited price impact; traders may monitor for any follow‑up activity.

03

What to watch

Potential upcoming clinical data or financing events could outweigh the insider sell.

Relevance 3/10Novelty 3/10Timing: after‑hours on filing day

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$BBIOBearishMedium confidence
Context

Chief Accounting Officer sold 2,000 shares for $145,700 via a 10b5-1 plan, reducing holdings to 120,687 shares.

Expected impact

likely modest pressure as the market prices in the insider sell.

Evidence & confidence

The sale is modest in size ($146K) and executed under a pre‑arranged plan, suggesting limited immediate impact but a potential bearish cue.

Market effects

Minimal effect on biotech sector; typical insider sales are routine.

No broader regional impact.

Limited to BBIO investors.

Counterpoint

The sale could be unrelated to fundamentals and may not affect price.

Key entities

  • Apuli Maricel

    Chief Accounting Officer of BridgeBio Pharma, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.